{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:51:08Z","timestamp":1780631468288,"version":"3.54.1"},"reference-count":61,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81102365"],"award-info":[{"award-number":["81102365"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973227"],"award-info":[{"award-number":["81973227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"research foundation of education bureau of Liaoning province","award":["2019LZD02"],"award-info":[{"award-number":["2019LZD02"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Human Cav1.3 (hCav1.3) is of great interest as a potential target for Parkinson\u2019s disease. However, common medications like dihydropyridines (DHPs), a kind of classic calcium channel blocker, have poor selectivity to hCav1.3 in clinical treatment, mainly due to being implicated in cardiovascular side-effects mediated by human Cav1.2 (hCav1.2). Recently, pyrimidine-2,4,6-triones (PYTs) have received extensive attention as prominent selective inhibitors to hCav1.3. In this study, we describe the selectivity mechanism of PYTs for hCav1.2 and hCav1.3 based on molecular dynamic simulation methods. Our results reveal that the van der Waals (vdW) interaction was the most important force affecting selectivity. Moreover, the hydrophobic interaction was more conducive to the combination. The highly hydrophobic amino acid residues on hCav1.3, such as V162 (IR1), L303 (IR2), M481 (IR3), and F484 (IR3), provided the greatest contributions in the binding free energy. On the other hand, the substituents of a halogen-substituted aromatic ring, cycloalkyl and norbornyl on PYTs, which are pertinent to the steric hindrance of the compounds, played core roles in the selectivity and affinity for hCav1.3, whereas strong polar substituents needed to be avoided. The findings could provide valuable information for designing more effective and safe medicines for Parkinson\u2019s disease.<\/jats:p>","DOI":"10.3390\/molecules25225440","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T11:50:34Z","timestamp":1606132234000},"page":"5440","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Investigation of the Selectivity of L-Type Voltage-Gated Calcium Channels 1.3 for Pyrimidine-2,4,6-Triones Derivatives Based on Molecular Dynamics Simulation"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-0530","authenticated-orcid":false,"given":"Qi","family":"Ye","sequence":"first","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Ding","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghai","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbo","family":"Song","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/138161206775474503","article-title":"L-type calcium channels","volume":"12","author":"Triggle","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/pr.114.009654","article-title":"The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential","volume":"67","author":"Zamponi","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pharmthera.2004.12.003","article-title":"Mouse models to study L-type calcium channel function","volume":"106","author":"Moosmang","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1152\/jn.00486.2004","article-title":"L-Type Calcium Channels: The Low Down","volume":"92","author":"Lipscombe","year":"2004","journal-title":"J. Neurophysiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/pr.57.4.5","article-title":"International Union of Pharmacology. XLVIII. Nomenclature and Structure-Function Relationships of Voltage-Gated Calcium Channels","volume":"57","author":"Catterall","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1152\/physrev.00016.2013","article-title":"L-Type CaV1.2 Calcium Channels: From In Vitro Findings to In Vivo Function","volume":"94","author":"Hofmann","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1126\/science.1716787","article-title":"The roles of the subunits in the function of the calcium channel","volume":"253","author":"Singer","year":"1991","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.biocel.2017.03.010","article-title":"L-type calcium channel: Clarifying the \u201coxygen sensing hypothesis\u201d","volume":"86","author":"Szappanos","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.tips.2011.02.012","article-title":"Structural and functional differences between L-type calcium channels: Crucial issues for future selective targeting","volume":"32","author":"Zuccotti","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.bmc.2013.04.054","article-title":"Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics","volume":"21","author":"Kang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00424-009-0753-0","article-title":"CaV1.2 channelopathies: From arrhythmias to autism, bipolar disorder, and immunodeficiency","volume":"460","author":"Liao","year":"2010","journal-title":"Pfl\u00fcg. Arch. Eur. J. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nn.2694","article-title":"Loss of Cav1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness","volume":"14","author":"Baig","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1021\/jm301839q","article-title":"Ligand Based Approach to L-Type Calcium Channel by Imidazo[2,1-b]thiazole-1,4-Dihydropyridines: From Heart Activity to Brain Affinity","volume":"56","author":"Locatelli","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1085\/jgp.200709946","article-title":"Ion Channels as Drug Targets: The Next GPCRs","volume":"131","author":"Kaczorowski","year":"2008","journal-title":"J. Gen. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1085\/jgp.200910308","article-title":"Molecular endpoints of Ca2+\/calmodulin- and voltage-dependent inactivation of Cav1.3 channels","volume":"135","author":"Tadross","year":"2010","journal-title":"J. Gen. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2174\/0929867311320100005","article-title":"Ion Channels as Drug Targets in Central Nervous System Disorders","volume":"20","author":"Waszkielewicz","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"\u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson\u2019s disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"ref_18","unstructured":"McDonough, S.I. (2011). Calcium Channel Pharmacology, Springer Science & Business Media."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Adachi-Akahane, S., and Nagao, T. (2000). Ca2+ channel antagonists and agonists. Pharmacology of Ionic Channel Function: Activators and Inhibitors, Springer.","DOI":"10.1007\/978-3-642-57083-4_5"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0165-6147(98)01171-7","article-title":"Structural basis of drug binding to L Ca2+ channels","volume":"19","author":"Striessnig","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/1874467208666150507105845","article-title":"Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?","volume":"8","author":"Striessnig","year":"2015","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vascn.2016.11.002","article-title":"L-type calcium channel antagonism\u2014Translation from in vitro to in vivo","volume":"84","author":"Fermini","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19006","DOI":"10.1074\/jbc.M109.011296","article-title":"Structural Model for Dihydropyridine Binding to L-type Calcium Channels","volume":"284","author":"Tikhonov","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/mol.108.049981","article-title":"Expression and 1,4-Dihydropyridine-Binding Properties of Brain L-Type Calcium Channel Isoforms","volume":"75","author":"Huber","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22100","DOI":"10.1074\/jbc.M101469200","article-title":"\u03b11D (Cav1.3) Subunits Can Form L-type Ca2+ Channels Activating at Negative Voltages","volume":"276","author":"Koschak","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1039\/c3md20345j","article-title":"Identification of 4,6-diaryl-1,4-dihydropyridines as a new class of neuroprotective agents","volume":"4","author":"Tenti","year":"2013","journal-title":"MedChemComm"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4149\/gpb_2009_03_249","article-title":"Haloperidol moderately inhibits cardiovascular L-type calcium current","volume":"28","author":"Lacinova","year":"2009","journal-title":"Gen. Physiol. Biophys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11077","DOI":"10.1002\/anie.201604336","article-title":"Unveiling (\u2212)-Englerin A as a Modulator of L-Type Calcium Channels","volume":"55","author":"Rodrigues","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/ncomms2149","article-title":"CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson\u2019s disease","volume":"3","author":"Kang","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1021\/jm4005048","article-title":"Structure\u2013Activity Relationship of N,N\u2032-Disubstituted Pyrimidinetriones as CaV1.3 Calcium Channel-Selective Antagonists for Parkinson\u2019s Disease","volume":"56","author":"Kang","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1021\/jm101549k","article-title":"Pyrimidine-2,4,6-trione Derivatives and Their Inhibition of Mutant SOD1-Dependent Protein Aggregation. Toward a Treatment for Amyotrophic Lateral Sclerosis","volume":"54","author":"Xia","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature12775","article-title":"Structural basis for Ca2+ selectivity of a voltage-gated calcium channel","volume":"505","author":"Tang","year":"2014","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature19321","article-title":"Structure of the voltage-gated calcium channel Ca v 1.1 at 3.6 \u00c5 resolution","volume":"537","author":"Wu","year":"2016","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1110\/ps.062416606","article-title":"Statistical potential for assessment and prediction of protein structures","volume":"15","author":"Shen","year":"2006","journal-title":"Protein Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/pro.5560020916","article-title":"Verification of protein structures: Patterns of nonbonded atomic interactions","volume":"2","author":"Colovos","year":"1993","journal-title":"Protein Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: A program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Crystallogr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF00228148","article-title":"AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR","volume":"8","author":"Laskowski","year":"1996","journal-title":"J. Biomol. NMR"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0263-7855(90)80070-V","article-title":"WHAT IF: A molecular modeling and drug design program","volume":"8","author":"Vriend","year":"1990","journal-title":"J. Mol. Graph."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms5481","article-title":"Modest Ca V 1.3 42-selective inhibition by compound 8 is \u03b2-subunit dependent","volume":"5","author":"Huang","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1038\/ncomms4897","article-title":"Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators","volume":"5","author":"Ortner","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W and Clustal X version 2.0","volume":"23","author":"Larkin","year":"2007","journal-title":"Bioinformatics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5.6.1","DOI":"10.1002\/cpbi.3","article-title":"Comparative Protein Structure Modeling Using MODELLER","volume":"54","author":"Webb","year":"2016","journal-title":"Curr. Protoc. Bioinform."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1039\/C5MB00781J","article-title":"Binding mechanisms of 1,4-dihydropyridine derivatives to L-type calcium channel Cav1.2: A molecular modeling study","volume":"12","author":"Xu","year":"2016","journal-title":"Mol. BioSyst."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jcc.23702","article-title":"CHARMM-GUIMembrane Buildertoward realistic biological membrane simulations","volume":"35","author":"Wu","year":"2014","journal-title":"J. Comput. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_46","unstructured":"Case, D.A., Cheatham, T.E., Simmerling, C.L., Wang, j., Duke, R.E., Luo, R., Walker, R.C., Zhang, W., Merz, K.M., and Roberts, B. (2016). Amber 16, University of California."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1021\/ct4010307","article-title":"Lipid14: The Amber Lipid Force Field","volume":"10","author":"Dickson","year":"2014","journal-title":"J. Chem. Theory Comput."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: AnN\u22c5log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1063\/1.1332996","article-title":"Langevin stabilization of molecular dynamics","volume":"114","author":"Izaguirre","year":"2001","journal-title":"J. Chem. Phys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10115","DOI":"10.1063\/1.477703","article-title":"Equilibration and sampling in molecular dynamics simulations of biomolecules","volume":"109","author":"Stella","year":"1998","journal-title":"J. Chem. Phys."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"061901","DOI":"10.1103\/PhysRevE.74.061901","article-title":"Equilibration of experimentally determined protein structures for molecular dynamics simulation","volume":"74","author":"Walton","year":"2006","journal-title":"Phys. Rev. E"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theory Comput."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the Performance of the MM\/PBSA and MM\/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/ct700119m","article-title":"Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms","volume":"3","author":"Shao","year":"2007","journal-title":"J. Chem. Theory Comput."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"ref_60","unstructured":"DeLano, W.L. (2015). The PyMOL Molecular Graphics System, Vearsion 1.8, Schr\u00f6dinger, LLC."},{"key":"ref_61","unstructured":"BioVia (2019). Discovery Studio 2019, BioVia."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/22\/5440\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:35:14Z","timestamp":1760178914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/22\/5440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":61,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["molecules25225440"],"URL":"https:\/\/doi.org\/10.3390\/molecules25225440","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]}}}